Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
about
In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosisNew Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal CancerP21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancerPosttranscriptional regulation of cancer traits by HuRClinicopathological and immunohistochemical analysis of gastrointestinal stromal tumorLoss of p21 disrupts p14 ARF-induced G1 cell cycle arrest but augments p14 ARF-induced apoptosis in human carcinoma cells.Induction of p21CIP/WAF-1 and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells.Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profilingEffects of activin and TGFβ on p21 in colon cancerAdjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients.Expression of p21WAF1 in Astler-Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy.p14ARF induces apoptosis via an entirely caspase-3-dependent mitochondrial amplification loop.Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancerDeath receptors in chemotherapy and cancer.The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapyEffectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell linesThe Prognostic Impact of p53 Expression on Sporadic Colorectal Cancer Is Dependent on p21 StatusHigh Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction.Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapyMolecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.Adjuvant therapy for rectal cancerLocally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2.Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer.The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.CGK733-induced LC3 II formation is positively associated with the expression of cyclin-dependent kinase inhibitor p21Waf1/Cip1 through modulation of the AMPK and PERK/CHOP signaling pathways.Small double-stranded RNA mediates the anti-cancer effects of p21WAF1/ClP1 transcriptional activation in a human glioma cell line.Correlation of expression of human arrest-defective-1 (hARD1) protein with breast cancer.On biomarkers and pathways in rectal cancer: What's the target?Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation.Immunohistological expression of HIF-1α, GLUT-1, Bcl-2 and Ki-67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer.Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.Long-term outcomes in patients with locally advanced rectal cancer treated with preoperative chemoradiation followed by curative surgical resection.TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.The fate of irradiated tumor cells.
P2860
Q24813088-F72A08A2-AF0E-4BE3-B769-391547AAF3C5Q26786311-62C55E65-91DA-40DC-8C83-B696220944CDQ27852992-EA5B55E9-1DE2-4901-AD5E-9683CEFD7148Q28248667-B297A667-7B76-477C-9C91-F7090F8C13A1Q28251092-062ECFC3-B0C4-4E29-8D3F-B21FB1DE0983Q33212599-988E9BE3-0C5D-4481-A90C-ABC1B4B32923Q33228616-561D6DA7-D95A-4358-B408-CE9BE6B690B0Q33242983-D7CA150B-2CA6-44F5-AB3E-897DB0DC568DQ33517932-82DA10F6-4528-4405-AE89-C596F31723D0Q34326087-6AEF6002-5F2B-4BBA-A478-CE18C607C138Q34437609-B32EE3BE-34F1-453D-A201-D3791EFDC021Q34705611-DEE190EC-4C30-4D60-9F2C-A114252088BFQ34728302-7017DA32-553D-4CCF-BB33-E716B29FA17EQ35460703-37D436ED-7551-4FD0-839B-8E20B54752D6Q35743149-D7ECEEBF-11AD-434D-923A-CFBFD62EC7AFQ35867312-7D5DAB85-76D2-4EA8-BE9C-CA5C98469A78Q36216989-CB8182D6-96AE-4A43-9F26-218FE4493309Q36487139-B182BD84-C86A-483F-B223-4EE492782354Q36616040-C2BBCCEA-2C01-4ECC-ABBA-9639B8604CFDQ36753310-AED9F5B5-8FCB-42BC-AD1E-8CB920CED89BQ37129876-CB5969B8-E5DC-47AC-BDD0-857543B8BEAAQ37269734-3DDAC36F-E64C-48AB-99B3-41399F48F83BQ37271984-F6F85C82-E79C-48CE-A499-531268B1E7D0Q37350764-221705D1-45CE-4480-B945-653287BFDDC5Q37462241-F7F2E31F-33F6-4A73-8CA1-22F57ABF8AAAQ37598888-E7C5F432-FFF6-45FE-A5E9-23DAAE086FEEQ37697800-354B885E-79B4-4239-9DF5-023888C80A2DQ38019396-43CA5852-6160-454F-8EB3-C9286D7D5AF9Q38157864-3CCB11B9-2DFB-401B-BD8F-F751432352F2Q38261672-8A087BCF-65F8-4DD6-A4EE-45DEF7CC3BFFQ39023357-73B6D27E-1E96-48BF-B83A-A04E1EDC7179Q39775678-2989E5D4-EE4C-4FB8-B2F1-386352E2C6F6Q41170919-2E2D11C5-F0B3-493E-8993-960C53C933BBQ42323807-8C048C4F-942F-4FB3-8DB2-1DE142667097Q42669180-D6FAE1AD-A81E-472D-A5A5-10DA93FAFCC2Q43569725-257A14A8-2FBE-40AB-82EE-2A9D15B71CF6Q45017990-B350A020-009F-47AE-ACF8-924042CD2643Q45241659-F5651BD4-E13A-4CF3-A83B-45E79876B0BBQ46187727-85C229CD-3B0D-4CD1-94F5-6C766F7A533AQ46772707-018E3B52-C23A-4E83-847D-8A07F4258FEA
P2860
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Dynamic expression profile of ...... reoperative radiochemotherapy.
@ast
Dynamic expression profile of ...... reoperative radiochemotherapy.
@en
type
label
Dynamic expression profile of ...... reoperative radiochemotherapy.
@ast
Dynamic expression profile of ...... reoperative radiochemotherapy.
@en
prefLabel
Dynamic expression profile of ...... reoperative radiochemotherapy.
@ast
Dynamic expression profile of ...... reoperative radiochemotherapy.
@en
P2093
P356
P1476
Dynamic expression profile of ...... reoperative radiochemotherapy.
@en
P2093
Bernd Dörken
Hanno Riess
Hermann Lage
Isrid Sturm
Peter M Schlag
Peter T Daniel
Peter Wust
Stefan Berger
Steffen Hauptmann
P304
P356
10.1200/JCO.2003.07.077
P407
P577
2003-07-28T00:00:00Z